Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine
作者： Sara S Bashraheel , Alexander Domling , Sayed K Goda
DOI: 10.1016/J.BIOPHA.2020.110009
关键词: Cancer 、 Personalized medicine 、 Cancer immunotherapy 、 Electronic data 、 Disease 、 Antibody-drug conjugate 、 Medicine 、 Precision medicine 、 Bioinformatics 、 Targeted therapy 、 Pharmacology 、 General Medicine
摘要: Background Until recently, patients who have the same type and stage of cancer all receive the same treatment. It has been established, however, that individuals with the same …
elsevier.com
sci-hub.se 参考文章(234)
Jiantao Hu, Biao Hu, Mingliang Wang, Fuming Xu, Bukeyan Miao, Chao-Yie Yang, Mi Wang, Zhaomin Liu, Daniel F. Hayes, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, Shaomeng Wang, Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). Journal of Medicinal Chemistry. ,vol. 62, pp. 1420- 1442 ,(2019) , 10.1021/ACS.JMEDCHEM.8B01572
Xin Han, Chao Wang, Chong Qin, Weiguo Xiang, Ester Fernandez-Salas, Chao-Yie Yang, Mi Wang, Lijie Zhao, Tianfeng Xu, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, Shaomeng Wang, Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. ,vol. 62, pp. 941- 964 ,(2019) , 10.1021/ACS.JMEDCHEM.8B01631
Blake E. Smith, Stephen L. Wang, Saul Jaime-Figueroa, Alicia Harbin, Jing Wang, Brian D. Hamman, Craig M. Crews, Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase Nature Communications. ,vol. 10, pp. 131- 131 ,(2019) , 10.1038/S41467-018-08027-7
Christian Steinebach, Hannes Kehm, Stefanie Lindner, Lan Phuong Vu, Simon Köpff, Álvaro López Mármol, Corinna Weiler, Karl G. Wagner, Michaela Reichenzeller, Jan Krönke, Michael Gütschow, PROTAC-mediated crosstalk between E3 ligases. Chemical Communications. ,vol. 55, pp. 1821- 1824 ,(2019) , 10.1039/C8CC09541H
Yoriko Yamashita-Kashima, Yasushi Yoshimura, Takaaki Fujimura, Sei Shu, Mieko Yanagisawa, Keigo Yorozu, Koh Furugaki, Ryota Higuchi, Junichi Shoda, Naoki Harada, Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Cancer Chemotherapy and Pharmacology. ,vol. 83, pp. 659- 671 ,(2019) , 10.1007/S00280-019-03768-8
Adam Bohr, Thais Nascimento, Necati Harmankaya, Johan Weisser, Yingya Wang, Holger Grohganz, Thomas Rades, Korbinian Löbmann, Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules. ,vol. 24, pp. 266- ,(2019) , 10.3390/MOLECULES24020266
Jianying Jin, Qunyi Guo, Jingjing Xie, Dan Jin, Yanan Zhu, Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer. Pathology & Oncology Research. ,vol. 25, pp. 769- 775 ,(2019) , 10.1007/S12253-019-00592-6
Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, Neal E. Rothschild, Lynn E. Spitler, C. Lance Cowey, Aaron R. Alizadeh, April K. Salama, Yi He, Thomas R. Hawthorne, Rebecca G. Bagley, Joshua Zhang, Christopher D. Turner, Omid Hamid, A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. ,vol. 125, pp. 1113- 1123 ,(2019) , 10.1002/CNCR.31892
Filippo Montemurro, Paul Ellis, Antonio Anton, Rachel Wuerstlein, Suzette Delaloge, Jacques Bonneterre, Nathalie Quenel-Tueux, Sabine C. Linn, Natsumi Irahara, Margarita Donica, Nicolas Lindegger, Carlos H. Barrios, Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1 European Journal of Cancer. ,vol. 109, pp. 92- 102 ,(2019) , 10.1016/J.EJCA.2018.12.022
Julie Biemar, Isabelle Nanni, L’houcine Ouafik, Stéphane Garcia, Julien Mazières, Fabrice Barlesi, Céline Mascaux, Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. ,vol. 14, pp. 1095- 1101 ,(2019) , 10.1016/J.JTHO.2019.01.011